World-Class Drug
Development Capabilities

Our oncology program focuses on selective inhibition of α_vβ₈, an integrin that can activate TGF-β in the tumor microenvironment, causing an anti-inflammatory effect and potential resistance to immuno-oncology therapeutics such as checkpoint inhibitors.

We recently announced interim Phase 1 data with antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types.

Muscular dystrophy comprises a group of inherited diseases, all characterized by inborn errors in dystrophin, a protein that anchors muscle cells to the extracellular matrix and facilitates contraction.  The lack of dystrophin results in muscle cell damage upon contraction, causing a progressive loss of muscle function over time.

We have identified PLN-101325, an α₇β₁ integrin activating antibody that acts as a compensatory anchor for muscle cells in patients with Duchenne muscular dystrophy, as well as other types of muscular dystrophy. Utilizing PLN-101325 to activate α₇β₁, we have shown in animal models the ability to increase muscle strength and decrease muscle damage caused by contraction. This program is currently Phase 1 ready.